Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Comments to Pharmacy Compounding Advisory…
Learn more
BIO Comments on OMB Proposed Rule "Regulation for…
Learn more
CSBA Letter to OMB
Learn more
All Letters, Testimony & Comments
  • Show All
Search
BIO Comments to Pharmacy Compounding Advisory Committee
July 23, 2026
CSBA Letter to OMB
July 13, 2026
BIO Comments on OMB Proposed Rule "Regulation for Federal Financial Assistance"
July 13, 2026
BIO Testimony on “Medicines and IP: Balancing Innovation and Access” to the Subcommittee on Intellectual Property, Artificial Intelligence, and the Internet
June 4, 2026
BIO Letter of Support for SECURE Data Act
June 4, 2026
BIO Comments on DoL Proposed Rule, “Improving Transparency into Pharmacy Benefit Manager Fee Disclosure”
April 15, 2026
John F. Crowley's Annual Letter to BIO Membership
April 8, 2026
Dear Colleagues,  I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…
BIO Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model (CMS-5545-P)
February 23, 2026
BIO Comments on Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (CMS-5546-P)
February 23, 2026
Testimony of John F. Crowley President and CEO, BIO House Committee on Energy and Commerce Subcommittee on Health Hearing on “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain"
February 11, 2026
Chairman Griffith, Chairman Guthrie, Ranking Member DeGette, Ranking Member Pallone, and distinguished members of the subcommittee, thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO)…